Liver function may change how belapectin works in the body

NCT ID NCT04332432

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks at how the drug belapectin moves through the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. Participants receive a single intravenous dose, and researchers measure drug levels in the blood over time. The goal is to understand if liver function affects how the drug is processed, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
belapectin (GR-MD-02), a drug given intravenously
What this could lead to
If successful, this study could help determine safe dosing of belapectin for people with liver problems.
What could go wrong
This is an early-phase study with only 38 participants, so results may not apply broadly. The drug's effectiveness for any condition is not being tested here.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Pharmacology of Miami, Inc

    Miami, Florida, 33014-3616, United States

  • Inland Empire Clinical Trials

    Rialto, California, 92377, United States

  • Pinnacle Clinical Research

    San Antonio, Texas, 78229, United States

  • Texas Liver Institute

    San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.